Trial Profile
An Open-Label Proof of Concept Phase IIa Trial of ALXN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid Syndrome
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2023
Price :
$35
*
At a glance
- Drugs Olendalizumab (Primary)
- Indications Antiphospholipid syndrome
- Focus Adverse reactions; Proof of concept
- Sponsors Alexion AstraZeneca Rare Disease
- 18 Dec 2021 This trial has been completed in Italy (End date:2016-06-20) as per European Clinical Trials Database record.
- 14 Jun 2017 Status changed from completed to discontinued.
- 02 Sep 2016 Status changed from active, no longer recruiting to completed.